S. Diessel

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment

T. Forst, A. Pfützner, A. Löffler, 2014, Diabetes/metabolism research and reviews.

Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients

G. Michelson, C. Kapitza, T. Forst, 2016, Journal of hypertension.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.